|
|
|
By AR Welch, Editorial & Community Director, Advancing RNA | It goes without saying that there’s a lot we need to understand about what impacts our drug products’ potency and safety. But I also appreciated the panels’ focus on the importance of gaining a clearer understanding of the biological factors that influence the strength, durability, immunogenicity, and overall deliverability of our RNA therapeutics in vivo. |
|
|
|
By BioPhorum | This article demystifies the manufacture of mRNA encapsulated in lipid nanoparticles across unit operations for plasmid linearization, drug substance (DS) manufacture, and drug product (DP) manufacture. |
|
|
|
By S. Lugo and K. Eerik Kaseniit, Co-Founders, Radar Therapeutics | This article by Radar Therapeutics explains why the DNA/RNA revolution is underway and why solving specific targeting is next. |
|
|
|
|
|
| Empowering A New Era Of Patient-Centric Medicines | Podcast | Nanoform | Discover the challenges pharma companies are facing as they switch focus as well as the actions and technologies companies are implementing to help achieve a brighter future for patients. |
|
|
|
| Potent Immune Response With Vernal's LNP-mRNAs | Article | By Julia Sakamoto, Vernal Biosciences | As mRNA medicine continues to evolve, understand how trusted manufacturing partners will continue to play a pivotal role in translating innovative concepts into clinical reality. |
|
|
.png){kind=logo}
